These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 29649923)

  • 41. [Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis].
    Popova EV; Boyko AN; Orlova EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):68-72. PubMed ID: 28139614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH; Wakefield RA
    Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate.
    Mayer L; Fink MK; Sammarco C; Laing L
    Drug Saf; 2018 Apr; 41(4):347-356. PubMed ID: 29218681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies.
    Montes Diaz G; Hupperts R; Fraussen J; Somers V
    Autoimmun Rev; 2018 Dec; 17(12):1240-1250. PubMed ID: 30316988
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
    Deeks ED
    Drugs; 2016 Feb; 76(2):243-54. PubMed ID: 26689201
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Delayed hypersensitivity to dimethyl fumarate: Report of 1 case and literature review.
    Baglivo I; Colantuono S; Caruso C; De Fino C; Gasbarrini A; Capone M; D'Amore A; Peris K; Romano A; Parronchi P
    J Allergy Clin Immunol Pract; 2023 May; 11(5):1562-1563.e2. PubMed ID: 36706983
    [No Abstract]   [Full Text] [Related]  

  • 48. Dimethyl fumarate induced migrating polyarthralgias.
    Villedon de Naide M; Moisset X; Soubrier M
    Joint Bone Spine; 2019 May; 86(3):399-400. PubMed ID: 30081200
    [No Abstract]   [Full Text] [Related]  

  • 49. Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis.
    Mills EA; Ogrodnik MA; Plave A; Mao-Draayer Y
    Front Neurol; 2018; 9():5. PubMed ID: 29410647
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diffuse dermatophytosis occurring on dimethyl fumarate therapy.
    Greenstein JI
    Mult Scler; 2018 Jun; 24(7):999-1001. PubMed ID: 29649923
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis.
    Valencia-Sanchez C; Carter JL
    Expert Opin Pharmacother; 2020 Aug; 21(12):1399-1405. PubMed ID: 32543241
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
    Zecca C; Antozzi CG; Torri Clerici V; Ferrazzini M; Mantegazza RE; Rossi S; Gobbi C
    Acta Neurol Scand; 2018 Jun; 137(6):623-625. PubMed ID: 29205270
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature.
    Dello Russo C; Scott KA; Pirmohamed M
    Pharmacol Ther; 2021 Mar; 219():107710. PubMed ID: 33091427
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis.
    Borrelli S; Mathias A; Goff GL; Pasquier RD; Théaudin M; Pot C
    Mult Scler Relat Disord; 2022 Jul; 63():103887. PubMed ID: 35636269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 3.